Nothing Special   »   [go: up one dir, main page]

EE02962B1 - Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid - Google Patents

Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid

Info

Publication number
EE02962B1
EE02962B1 EE9400388A EE9400388A EE02962B1 EE 02962 B1 EE02962 B1 EE 02962B1 EE 9400388 A EE9400388 A EE 9400388A EE 9400388 A EE9400388 A EE 9400388A EE 02962 B1 EE02962 B1 EE 02962B1
Authority
EE
Estonia
Prior art keywords
preparation
pharmaceutical compositions
mometasone furoate
furoate monohydrate
monohydrate
Prior art date
Application number
EE9400388A
Other languages
English (en)
Estonian (et)
Inventor
Yuen Pui-Ho
Eckhart Charles
Etlinger Teresa
Levine Nancy
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE02962(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of EE02962B1 publication Critical patent/EE02962B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EE9400388A 1990-09-10 1994-11-21 Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid EE02962B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10

Publications (1)

Publication Number Publication Date
EE02962B1 true EE02962B1 (et) 1997-02-17

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400388A EE02962B1 (et) 1990-09-10 1994-11-21 Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid

Country Status (35)

Country Link
US (1) US6180781B1 (sl)
EP (1) EP0548114B1 (sl)
JP (1) JPH0725789B2 (sl)
KR (1) KR960013445B1 (sl)
CN (1) CN1030920C (sl)
AT (1) ATE113604T1 (sl)
AU (1) AU663471B2 (sl)
BG (1) BG60755B2 (sl)
CA (1) CA2091360C (sl)
CZ (1) CZ281318B6 (sl)
DE (2) DE69104991T2 (sl)
DK (1) DK0548114T5 (sl)
EE (1) EE02962B1 (sl)
ES (1) ES2065701T3 (sl)
FI (1) FI111078B (sl)
HK (1) HK185996A (sl)
HR (1) HRP920383B1 (sl)
HU (1) HU213401B (sl)
IE (1) IE67056B1 (sl)
IL (1) IL99437A (sl)
LU (1) LU90366I2 (sl)
MX (2) MX9203396A (sl)
MY (1) MY106644A (sl)
NL (1) NL980012I2 (sl)
NO (1) NO300548B1 (sl)
NZ (1) NZ239711A (sl)
OA (1) OA09772A (sl)
PH (1) PH30443A (sl)
PL (1) PL165803B1 (sl)
PT (1) PT98905B (sl)
SI (1) SI9111497A (sl)
TW (2) TW229208B (sl)
WO (1) WO1992004365A1 (sl)
YU (1) YU48666B (sl)
ZA (1) ZA917148B (sl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113604T1 (de) * 1990-09-10 1994-11-15 Schering Corp Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
AU9674398A (en) * 1997-10-09 1999-05-03 Schering Corporation Mometasone furoate suspensions for nebulization
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
AR045536A1 (es) * 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
EP1948164A1 (en) 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of muscarinic receptor antagonists
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
KR20090069309A (ko) * 2006-09-22 2009-06-30 랜박시 래보러터리스 리미티드 포스포디에스터라제 타입-ⅳ의 저해제
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
AP2453A (en) 2007-03-14 2012-08-31 Ranbaxy Lab Ltd Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
DK2435024T3 (en) 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
ATE113604T1 (de) * 1990-09-10 1994-11-15 Schering Corp Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.

Also Published As

Publication number Publication date
IE67056B1 (en) 1996-02-21
AU663471B2 (en) 1995-10-12
HU9300685D0 (en) 1993-06-28
FI931031A0 (fi) 1993-03-09
ZA917148B (en) 1992-08-26
MX9100990A (es) 1992-05-04
MX9203396A (es) 1992-07-31
SI9111497A (sl) 1998-04-30
US6180781B1 (en) 2001-01-30
PL165803B1 (pl) 1995-02-28
IE913155A1 (en) 1992-03-11
NO930693D0 (no) 1993-02-26
FI931031A (fi) 1993-03-09
ES2065701T3 (es) 1995-02-16
DE69104991T2 (de) 1995-04-20
NL980012I1 (nl) 1998-05-06
HRP920383B1 (en) 2000-04-30
YU48666B (sh) 1999-06-15
CZ38393A3 (en) 1994-01-19
IL99437A (en) 1995-05-29
CN1030920C (zh) 1996-02-07
WO1992004365A1 (en) 1992-03-19
TW272195B (sl) 1996-03-11
CZ281318B6 (cs) 1996-08-14
OA09772A (en) 1993-11-30
AU8497491A (en) 1992-03-30
HRP920383A2 (en) 1998-06-30
CN1059911A (zh) 1992-04-01
DE69104991D1 (de) 1994-12-08
PT98905A (pt) 1992-09-30
IL99437A0 (en) 1992-08-18
NO300548B1 (no) 1997-06-16
ATE113604T1 (de) 1994-11-15
KR960013445B1 (ko) 1996-10-05
TW229208B (sl) 1994-09-01
CA2091360C (en) 1997-04-08
CA2091360A1 (en) 1992-03-11
HU213401B (en) 1997-06-30
DK0548114T5 (da) 1995-01-30
PH30443A (en) 1997-05-09
JPH0725789B2 (ja) 1995-03-22
PT98905B (pt) 1998-08-31
BG60755B2 (bg) 1996-02-29
HK185996A (en) 1996-10-11
FI111078B (fi) 2003-05-30
NO930693L (no) 1993-02-26
YU149791A (sh) 1994-01-20
NZ239711A (en) 1992-09-25
EP0548114A1 (en) 1993-06-30
JPH05506667A (ja) 1993-09-30
DE19875032I2 (de) 2007-04-19
LU90366I2 (fr) 1999-05-05
MY106644A (en) 1995-07-31
EP0548114B1 (en) 1994-11-02
NL980012I2 (nl) 2004-11-01
HUT64361A (en) 1993-12-28

Similar Documents

Publication Publication Date Title
EE02962B1 (et) Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
SE8300736D0 (sv) Novel pharmacologically active compounds
ATE255589T1 (de) Kristallin form i von clarithromycin
ATE22562T1 (de) 6-substituierte s-triazolo(3,4-a)phthalazinderivate.
RU93004445A (ru) Новые 2-циано 3-гидроксиенамидные производные, способ их получения, их применение в качестве медикаментов, содержащие их фармацевтические композиции и новые полученные промежуточные продукты
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
NZ192195A (en) 1-triazolyl-2-hydroxy-2-phenyl-3-aryl-propanes and pharmaceutical compositions
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
IL47529A (en) Substituted (1-(-4,4-bisphenylbutyl)-4-piperidyl-)1,3-dihydro-2h-benzimidazol-2-one derivatives and certain intermediates for obtaining such compounds,their preparation and pharmaceutical compositions containing them
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
IT7927243A0 (it) Per la loro preparazione e composti triazinonici, procedimenti composizioni farmaceutiche che licontengono.
PH23039A (en) N-substituted aziridine-2-carboxylic acid derivatives and pharmaceutical composition containing them
ES474052A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridazinas 1-n-sustituidas.
IT8421627A0 (it) Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo.
IT8220979A0 (it) Derivato della propionilglicina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono come principio attivo.

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

HC1A Change of owner name